Impact Factor: 3,34
Abstracts will be published in
Journal of Biotechnology

Confirmed Speakers

Uldis Berzinś

Uldis Bērziņš, MD is a chief executive officer of a company "Cilmes šūnu tehnoloģijas" Ltd. (Stem Cell Technologies), a spin-off from Latvian Biomedical Research and Study Centre LBMC), established on the basis of acquired experience in cell research and clinical embryology. The company works towards developing and implementing Advanced Therapy Medicinal Products (ATMPs) under the hospital exemption scheme (implementation of Art 28(2) of Regulation 1394/2007) in Latvia. The main areas of interest include: (i) Manufacturing of cellular therapy products (CTP) and associated problems, and (ii) CTP potency testing before clinical phase.

<< back